Updated Jun 23, 10:48 PM · 60 sources analyzed
Key Takeaways
AstraZeneca terminated its entire brazikumab IBD program across four studies, signaling a full exit from the IL-23 GI space.
Boehringer Ingelheim also terminated a Phase 2/3 spesolimab extension in hidradenitis suppurativa, narrowing that asset's label expansion prospects.
MapLight Therapeutics and Verastem each filed material 8-Ks; full disclosure content will determine whether either represents a meaningful catalyst.
📉 Loser
AstraZeneca — terminated its full brazikumab IBD program across Crohn's disease, ulcerative colitis, and an open-label extension, representing a clean exit from a competitive and commercially valuable space
🔭 Watch Next
Cardiol Therapeutics' completed Phase 2 of CardiolRx in acute myocarditis has no approved competitors; data disclosure from NCT05180240 — expected imminently — will be the next meaningful signal from today's registry updates.
AstraZeneca Quietly Kills Brazikumab IBD Program
AstraZeneca has terminated multiple Phase 2 and Phase 3 trials of brazikumab, an IL-23 inhibitor, across both ulcerative colitis and Crohn's disease, with the trials now marked terminated on ClinicalTrials.gov. The simultaneous termination across four studies — including a Phase 3 Crohn's trial and an open-label extension — signals a full program discontinuation rather than a strategic pause. The IBD biologics market is fiercely competitive, with approved IL-23 inhibitors from AbbVie, Johnson & Johnson, and Eli Lilly already entrenched, and AstraZeneca's exit removes a would-be challenger from the field.
ClinicalTrials.gov ↗AstraZeneca
Brazikumab in Crohn's Disease
The Phase 2/3 study (NCT03759288) comparing brazikumab versus placebo and an active comparator in moderately to severely active Crohn's disease has been marked terminated on ClinicalTrials.gov. No efficacy or safety data from this termination have been publicly released.
Why it matters
The simultaneous termination across Crohn's, ulcerative colitis, and an open-label extension suggests this was a portfolio-level decision, not a single study failure — AstraZeneca is effectively conceding the IL-23 IBD race to AbbVie's risankizumab, J&J's guselkumab, and Lilly's mirikizumab. For AstraZeneca, the opportunity cost is meaningful given how crowded and commercially valuable the IBD biologic market remains.
What to watch
Watch for AstraZeneca to provide an investor-facing explanation of the brazikumab discontinuation — either at its next pipeline update or R&D day — clarifying whether the decision was efficacy-driven, competitive, or capital allocation-related.
AstraZeneca
Brazikumab in Ulcerative Colitis
Both the Phase 2 placebo-controlled UC study (NCT03616821) and its open-label extension (NCT04277546) are now marked terminated on ClinicalTrials.gov. No outcome data have been released in connection with these terminations.
Why it matters
Terminating the OLE (open-label extension, a long-term safety and durability study) alongside the parent trials strongly implies AstraZeneca is not salvaging partial data for any future indication — this is a clean exit. Investors should note the write-down implications for any remaining capitalized R&D spend on the asset.
What to watch
Watch for any licensing or asset sale activity around brazikumab over the next 12 months — a smaller IBD-focused biotech may see value in the existing clinical package if termination was competition-driven rather than safety-driven.
Boehringer Ingelheim
Spesolimab in Hidradenitis Suppurativa (HS)
The Phase 2/3 long-term extension study of spesolimab in hidradenitis suppurativa (NCT06241573) has been marked terminated on ClinicalTrials.gov. No efficacy or safety outcome data from this termination have been disclosed.
Why it matters
HS is a high-value indication with limited approved options, so Boehringer pulling its OLE here likely reflects either futility signals from the parent studies or a competitive assessment against a crowded pipeline. The company will need to explain whether the parent studies also terminate or read out.
What to watch
Watch for status updates on the parent spesolimab HS studies (NCT05819398 and NCT05819398) to determine whether the OLE termination foreshadows broader program discontinuation in HS.
TI-374 Induces Alanine Auxotrophy as Novel Anti-TB Mechanism
A bioRxiv preprint reports that TI-374, a hydroxamic acid compound identified through drug repurposing, inhibits Mycobacterium tuberculosis at sub-micromolar concentrations by inducing alanine auxotrophy (making the bacterium unable to synthesize the amino acid alanine it needs to survive), a mechanism not previously exploited by approved TB drugs.
Why it matters
Drug repurposing platforms finding first-in-class mechanisms against Mtb are rare, and auxotrophy induction is an intellectually attractive strategy because it targets bacterial metabolism rather than a single enzyme. The caveat is that this is preprint-stage, preclinical data — the gap from sub-micromolar in vitro activity to a viable clinical candidate involves significant ADMET (absorption, distribution, metabolism, excretion, and toxicity) optimization that most compounds do not survive.
What to watch
Watch for peer-reviewed publication and whether the authors or a partner advance TI-374 or a derivative into IND-enabling studies, which would be the first signal that this mechanism is being taken seriously as a clinical candidate.
The Phase 2/3 study (NCT03759288) comparing brazikumab versus placebo and an active comparator in moderately to severely active Crohn's disease has been marked terminated on ClinicalTrials.gov. No efficacy or safety data from this termination have been publicly released.
Why it matters
Full withdrawal from the IBD space clears the field for entrenched IL-23 competitors and removes a late-stage pipeline asset from AstraZeneca's immunology roster.
Analysis
The simultaneous termination across Crohn's, ulcerative colitis, and an open-label extension suggests this was a portfolio-level decision, not a single study failure — AstraZeneca is effectively conceding the IL-23 IBD race to AbbVie's risankizumab, J&J's guselkumab, and Lilly's mirikizumab. For AstraZeneca, the opportunity cost is meaningful given how crowded and commercially valuable the IBD biologic market remains.
What to watch
Watch for AstraZeneca to provide an investor-facing explanation of the brazikumab discontinuation — either at its next pipeline update or R&D day — clarifying whether the decision was efficacy-driven, competitive, or capital allocation-related.
Both the Phase 2 placebo-controlled UC study (NCT03616821) and its open-label extension (NCT04277546) are now marked terminated on ClinicalTrials.gov. No outcome data have been released in connection with these terminations.
Why it matters
The UC terminations, taken together with the Crohn's program shutdown, confirm brazikumab is no longer in active development for any GI indication.
Analysis
Terminating the OLE (open-label extension, a long-term safety and durability study) alongside the parent trials strongly implies AstraZeneca is not salvaging partial data for any future indication — this is a clean exit. Investors should note the write-down implications for any remaining capitalized R&D spend on the asset.
What to watch
Watch for any licensing or asset sale activity around brazikumab over the next 12 months — a smaller IBD-focused biotech may see value in the existing clinical package if termination was competition-driven rather than safety-driven.
The Phase 2/3 long-term extension study of spesolimab in hidradenitis suppurativa (NCT06241573) has been marked terminated on ClinicalTrials.gov. No efficacy or safety outcome data from this termination have been disclosed.
Why it matters
Spesolimab already has FDA approval for generalized pustular psoriasis, but the HS termination narrows its label expansion prospects in a lucrative inflammatory skin disease market where AbbVie's bimekizumab is gaining ground.
Analysis
HS is a high-value indication with limited approved options, so Boehringer pulling its OLE here likely reflects either futility signals from the parent studies or a competitive assessment against a crowded pipeline. The company will need to explain whether the parent studies also terminate or read out.
What to watch
Watch for status updates on the parent spesolimab HS studies (NCT05819398 and NCT05819398) to determine whether the OLE termination foreshadows broader program discontinuation in HS.
The Phase 2 randomized, double-blind, placebo-controlled study of CardiolRx in acute myocarditis (NCT05180240) is now marked completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released in connection with this status update.
Why it matters
Myocarditis has no approved therapies and represents a genuine unmet need; a completed Phase 2 for a cannabidiol formulation is a signal that data disclosure is imminent and worth tracking for this small-cap company.
Analysis
For a micro-cap like Cardiol, a completed Phase 2 in an indication with no approved drugs is the kind of catalyst that can move the stock significantly — but only if the data are compelling. The absence of a simultaneous press release at trial completion is either a sign of disciplined disclosure timing or an ominous silence.
What to watch
Watch for Cardiol Therapeutics to release Phase 2 efficacy data from NCT05180240 at a cardiology conference or via press release in the coming weeks.
The Phase 2 randomized, double-blind, placebo-controlled study of CLE-100 as adjunctive therapy for MDD in patients with inadequate response to standard antidepressants (NCT06340958) is now marked completed on ClinicalTrials.gov. No efficacy or safety data have been released alongside this status update.
Why it matters
Oral esketamine is a differentiated formulation play on an approved mechanism (J&J's Spravato is intranasal), and Phase 2 data here could define whether an oral route offers a commercially viable convenience advantage.
Analysis
The MDD adjunctive therapy space is crowded but oral bioavailability remains a genuine differentiator from Spravato's REMS-restricted in-office administration. Clexio's data will need to show not just efficacy but a clean enough safety profile to support outpatient oral dosing — that is the real story investors should be watching for.
What to watch
Watch for Clexio to present or publish Phase 2 efficacy and tolerability data from NCT06340958, which will determine whether an oral esketamine formulation can justify further clinical investment.
TI-374 Induces Alanine Auxotrophy as Novel Anti-TB Mechanism
A bioRxiv preprint reports that TI-374, a hydroxamic acid compound identified through drug repurposing, inhibits Mycobacterium tuberculosis at sub-micromolar concentrations by inducing alanine auxotrophy (making the bacterium unable to synthesize the amino acid alanine it needs to survive), a mechanism not previously exploited by approved TB drugs.
Why it matters
A genuinely new mechanism of action against Mtb could address the growing problem of resistance to existing regimens and provide a combinability advantage with bedaquiline- and linezolid-based backbones currently in late-stage development.
Analysis
Drug repurposing platforms finding first-in-class mechanisms against Mtb are rare, and auxotrophy induction is an intellectually attractive strategy because it targets bacterial metabolism rather than a single enzyme. The caveat is that this is preprint-stage, preclinical data — the gap from sub-micromolar in vitro activity to a viable clinical candidate involves significant ADMET (absorption, distribution, metabolism, excretion, and toxicity) optimization that most compounds do not survive.
What to watch
Watch for peer-reviewed publication and whether the authors or a partner advance TI-374 or a derivative into IND-enabling studies, which would be the first signal that this mechanism is being taken seriously as a clinical candidate.
NCI Phase 2 Tests HPV Vaccine PRGN-2009 Plus Pembrolizumab Before Surgery in Oropharyngeal Cancer
A National Cancer Institute-sponsored Phase 2 trial (NCT05996523) is actively enrolling to evaluate whether adding the therapeutic HPV vaccine PRGN-2009 to pembrolizumab (Keytruda) prior to standard definitive treatment can improve outcomes in newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma.
Why it matters
Neoadjuvant (pre-surgery) therapeutic vaccination combined with checkpoint blockade in a virally-driven tumor type represents a high-signal opportunity to generate tumor-specific T-cell responses before surgical debulking — a design that could validate the combination as a platform across HPV-associated cancers including cervical and anal.
Analysis
PRGN-2009 is a Precigen asset, and positive neoadjuvant data in oropharyngeal cancer would substantially strengthen the rationale for broader HPV-vaccine combination programs. The study's active-not-recruiting status means data could emerge within 12–18 months, making it a nearer-term catalyst than most early-phase immune-oncology combinations.
What to watch
Watch for primary efficacy data from NCT05996523, likely presented at a head-and-neck oncology or immunotherapy conference in 2027, which will determine whether pathologic complete response rates justify an accelerated approval strategy.
NCI Opens Phase 1/2 of Mirdametinib Plus Sirolimus for RAS-Mutated Relapsed/Refractory Multiple Myeloma
A Phase 1/2 NCI study (NCT06876142) combining mirdametinib (a MEK inhibitor — a drug that blocks a key cancer cell signaling protein) with sirolimus (an mTOR inhibitor) for RAS-mutated relapsed/refractory multiple myeloma is currently listed as suspended on ClinicalTrials.gov.
Why it matters
RAS mutations are present in roughly 20–30% of multiple myeloma cases and are associated with aggressive disease and resistance to standard therapies; rational combination of MEK and mTOR pathway inhibition in a biomarker-selected population is a scientifically sound approach with limited clinical precedent in myeloma.
Analysis
The suspended status warrants monitoring — it may reflect a temporary administrative hold rather than a safety signal, but it does mean this combination is not yet enrolling patients. If the suspension resolves, this becomes a meaningful early proof-of-concept study for RAS-targeted combinations in a hematologic malignancy where the unmet need after CAR-T and bispecific failure is acute.
What to watch
Watch for the study suspension to lift and first enrollment to be reported, which would confirm the combination has cleared any regulatory or safety review concerns and is advancing into dose escalation.
MapLight Therapeutics
MapLight Therapeutics filed an 8-K (Items 7.01, 8.01, 9.01) on June 22, 2026, indicating a material disclosure event — potentially a pipeline update, financing, or partnership announcement.
Why it matters
MapLight is a clinical-stage CNS company targeting metabotropic glutamate receptors, and any material 8-K filing from a company of this size warrants scrutiny for clinical or partnership news that could define near-term trajectory.
Analysis
Items 8.01 and 7.01 in combination typically signal a press release of operational or clinical significance rather than a routine administrative event — for a company like MapLight that is pre-revenue and pipeline-dependent, the substance of this filing could meaningfully shift the investment thesis. Full content review of the actual filing is required before drawing conclusions.
What to watch
Watch for the underlying press release or 8-K exhibit associated with MapLight's June 22 filing to determine whether this signals a clinical data readout, financing, or business development event.
Verastem
Verastem filed an 8-K (Items 7.01, 8.01, 9.01) on June 23, 2026, indicating a material press release disclosure — likely related to its RAF/MEK inhibitor combination program in RAS-driven cancers.
Why it matters
Verastem's pipeline is anchored by VS-6766 (avutometinib) combined with defactinib in RAS-mutated cancers including low-grade serous ovarian cancer, where it has Breakthrough Therapy Designation; any material update here carries direct implications for its ongoing FDA interactions and NDA timeline.
Analysis
An 8.01 filing from Verastem at this stage of its regulatory program is worth watching closely — the company is navigating a complex regulatory path for avutometinib/defactinib and any FDA communication or clinical update could accelerate or delay its anticipated approval timeline. Without the full exhibit, the valence of this news cannot be determined.
What to watch
Watch for the press release underlying Verastem's June 23 8-K to clarify whether this relates to FDA review progress, clinical data from the RAMP program, or a financing or partnership event.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.